Cardiology Trials
Cardiology Trials
An exploration of pivotal clinical trials in cardiovascular medicine that have significantly influenced the field. This podcast aligns with our publications on the Cardiology Trial's Substack. cardiologytrials.substack.com
Be sure to visit the podcast's website and support the creator: cardiologytrials.substack.com
Author
Cardiology Trials
Category
Podcast website
Latest episode
Oct 21, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Summary and discussion of IMPROVE-IT, CANTOS, CIRT and COLCOT 20.06.2024 50:44
For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
Review of the COLCOT trial 13.06.2024 9:28
N Engl J Med 2019;381:2497-2505 Background: Inflammation increases the risk of atherosclerosis, and reducing inflammation with canakinumab, a monoclonal antibody that neutralizes interleukin-1β, reduced plasma markers of inflammation and the risk of future myocardial infarctions but was associated with small yet statistically significant increased risk of fatal infections. Methotrexate, in the CIR...
Review of the CIRT trial 10.06.2024 9:30
N Engl J Med 2019;380:752-762 Background: Growing body of evidence suggests the role of inflammation in atherosclerosis. The CANTOS trial , discussed earlier, provided further evidence for that hypothesis. In the CANTOS trial, canakinumab a monoclonal antibody that neutralizes interleukin-1β led to fewer myocardial infarctions compared to placebo. Cardiology Trial’s Substack is a reader-supported...
Review of the CANTOS Trial 03.06.2024 11:31
N Engl J Med 2017;377:1119-1131 Background The hypothesis tested in the CANTOS Trial reflected an emerging view of atherosclerosis development and progression - that it was not simply a matter of plasma cholesterol but also systemic inflammation. In the manuscript’s introduction the authors cite data on the independent association of certain inflammatory markers with an increased risk of cardiovas...
Review of the IMPROVE-IT trial 28.05.2024 10:19
N Engl J Med 2015;372:2387-2397 Background: Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, effectively lower low-density lipoprotein (LDL) and improve cardiovascular outcomes across different populations. High-intensity statins exhibit greater efficacy in lowering LDL and decreasing non-fatal cardiac events compared to moderate-intensity statins. Nonetheless, due to the re...
Summary and discussion of ACCOAST and ISAR-REACT 5 23.05.2024 13:41
For full review of the trials, please see https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
Review of the ISAR-REACT 5 Trial 16.05.2024 8:52
N Engl J Med 2019;381:1524-1534 Background Dual antiplatelet therapy after percutaneous coronary intervention had become a standard of care. Both prasugrel and ticagrelor had been shown to provide more rapid and consistent platelet inhibition than clopidogrel. Randomized controlled trials had shown both drugs were superior to clopidogrel in patients with acute coronary syndromes. Cardiology Trial’...
Review of the ACCOAST trial 14.05.2024 7:39
N Engl J Med 2013;369:999-1010 Background: Adding P2Y12 inhibitors to aspirin improves outcomes in patients with acute coronary syndrome. Yet, debate persisted regarding the optimal timing for administering these drugs in patients undergoing percutaneous coronary intervention (PCI). The ATLANTIC trial showed that pre-hospital administration of ticagrelor did not improve outcomes compared to in-hos...
Summary and discussion of TACT and ATLANTIC 09.05.2024 34:22
For full review of the trials, please see our substack https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
Review of the ATLANTIC trial 02.05.2024 8:56
N Engl J Med 2014;371:1016-1027 Background: Prior trials have demonstrated that combining P2Y12 inhibitors with aspirin in patients with acute coronary syndrome reduces cardiovascular events. Prasugrel, in the TRITON-TIMI 38 trial, and ticagrelor, in the PLATO trial, were administered in the hospital. Cardiology Trial’s Substack is a reader-supported publication. To receive new posts and support...
Summary and discussion of NICE-SUGAR, TRITON-TIMI 38, TRILOGY ACS, PLATO and ATLAS ACS 2-TIMI 51 29.04.2024 54:48
See our substack for full review of these trials https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
Review of the TACT Trial 25.04.2024 8:28
JAMA. 2013;309(12):1241-1250 Background Case reports as early as the 1950s suggested chelation of lead might reduce angina. The popularity of chelation accelerated around the turn of the century. Small underpowered trials of chelation were inconclusive. Mainstream medicine considered chelation unproven and potentially hazardous. Cardiology Trial’s Substack is a reader-supported publication. To re...
Review of the ATLAS ACS 2-TIMI 51 trial 23.04.2024 11:55
N Engl J Med 2012;366:9-19 Background Following an acute coronary syndrome, individuals have a substantially elevated risk of recurrent events, compared to a similar individual who did not experience ACS, despite the use of appropriate risk reducing therapies. This is termed “residual risk” and the concept has been mentioned in prior reviews. The quest to lower residual risk continues to be a majo...
Review of the CURRENT-OASIS 7 trial 18.04.2024 8:22
N Engl J Med 2010;363:930-942 Background By 2010, dual antiplatelet therapy had been established as beneficial during and after percutaneous coronary intervention for acute coronary syndromes. Optimal dosing however remained unknown. This included the best loading dose of clopidogrel and optimal dose of aspirin. Cardiology Trial’s Substack is a reader-supported publication. To receive new posts an...
Review of the TRILOGY ACS trial 16.04.2024 10:27
N Engl J Med 2012;367:1297-1309 Background: In patients with acute coronary syndrome, clinical guidelines recommend early angiography particularly in those deemed moderate to high risk. However, a proportion of patients do not undergo revascularization, and these patients have poorer outcomes compared to those who do undergo revascularization. Cardiology Trial’s Substack is a reader-supported publ...
Review of the PLATO Trial 04.04.2024 13:43
N Engl J Med 2009;361:1045-57. Background Similar to Prasugrel, Ticagrelor is a direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12. Unlike clopidogrel that requires transformation of the prodrug to the active metabolite, Ticagrelor provides faster and more consistent P2Y12 inhibition. In the TRITON-TIMI 38 trial , Prasugrel compared to clopidogrel reduced myocardial infarcti...
Review of the TRITON-TIMI 38 Trial 02.04.2024 14:41
Note to readers: Since going live with Cardiology Trials Substack in January of 2024 we have been exclusively covering trials that we have categorized as belonging to the major subject heading “Acute Coronary Syndrome” belonging to the subsection “Medicines”. Our indexing scheme was described in one of our original posts and we encourage our audience to read it if you have not already. This is per...
Review of the HORIZONS-AMI trial 28.03.2024 7:54
N Engl J Med 2008; 358:2218-2230 Background The use of percutaneous coronary intervention (PCI) is associated with improved outcomes in patients with ST-segment elevation myocardial infarction (STEMI). Nonetheless, there was a need to further improve survival rates. As seen in OASIS-6, the 30-day mortality in the control arm was still high at 8.9%. Glycoprotein IIb/IIIa inhibitors emerged as a pot...
Review of the OASIS-6 trial 26.03.2024 9:07
JAMA. 2006;295(13):1519-1530 Background Previous trials demonstrated that aspirin and thrombolytic therapy improve prognosis in patients with ST elevation myocardial infarction (STEMI). The addition of heparin to aspirin and thrombolysis did not improve outcomes in patients with STEMI (see GISSI-2 trial). Fondaparinux, a synthetic pentasaccharide that inhibits factor Xa, was tested in OAISIS-5 , a...
Review of the OASIS-5 trial 12.03.2024 9:12
N Engl J Med 2006; 354:1464-1476 Background: Prior studies showed that combined antiplatelets and anticoagulants reduce ischemic events in patients with acute coronary syndrome but increases the risk of bleeding. We saw this in the FRISC trial where low-molecular-weight heparin plus aspirin reduced the primary endpoint of death or nonfatal myocardial infarction compared to placebo at 6 days but al...
Summary and discussion of CURE and DIGAMI 2 11.03.2024 48:41
Two trials in acute coronary syndrome - CURE (clopidogrel in acute coronary syndrome) and DIGAMI 2 (glucose control in acute coronary syndrome) Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
Review of DIGAMI 2 07.03.2024 9:40
European Heart Journal, Volume 26, Issue 7, 2005, 650–661 Background Patients with diabetes have a higher risk of death after myocardial infarction than those without diabetes. There are many possible reasons for this difference. One may be that diabetic patients have detrimental responses during the acute phase of MI. In the DIGAMI 1 trial, patients with diabetes and AMI were randomized to inten...
Review of the CURE Trial 05.03.2024 11:58
N Engl J Med 2001;345:494-502. Background The established medical treatments for acute coronary syndrome reviewed so far include aspirin and thrombolytics along with a smaller role for short-term anticoagulation. Angiotensin converting enzymes inhibitors and, to a lesser extent, beta blockers were also found to reduce recurrent ischemic events and death as well as heart failure and ventricular rem...
Summary and discussion of MIRACL and PROVE IT-TIMI 22 04.03.2024 49:57
Two trials of statin therapy in acute coronary syndrome. See https://cardiologytrials.substack.com/ for more details. Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
Review of the PROVE IT-TIMI 22 Trial 29.02.2024 9:37
NEJM 2004;350:1495-504. Background The benefit of cholesterol lowering with statins compared to placebo had been demonstrated in multiple trials across a range of cholesterol starting levels in patients with and without a history of coronary artery disease. The average reduction in cholesterol from baseline levels in these trials was in the range of 25% to 35%. Guidelines at the time this trial wa...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.